HR Execs on the Move

BioTime

www.biotimeinc.com

 
BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.biotimeinc.com
  • 1010 Atlantic Avenue Suite 102
    Alameda, CA USA 94501
  • Phone: 510.521.3390

Executives

Name Title Contact Details

Similar Companies

Oncothyreon

Oncothyreon is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fraunhofer Center for Molecular Biology

Fraunhofer Center for Molecular Biology is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akero Therapeutics

Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.

Tanox

Tanox, Inc. is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Medicenna Therapeutics Corporation

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna`s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna`s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna`s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.